8-K Announcements
6Material company update
Mar 26, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Jan 9, 2026·SEC
Athira Pharma, Inc.(ATHA)Earnings, Financials & Key Ratios
ATHA•NASDAQ
$4.34
$17M mkt cap·Price updated May 6, 2026
AboutAthira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.Show more
- Revenue$0
- EBITDA-$102M-2.3%
- Net Income-$106M-8.9%
- EPS (Diluted)-24.70+2.0%
- ROE-290.81%-162.5%
- Debt/Equity0.03+6.5%
ATHA Key Insights
Athira Pharma, Inc. (ATHA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Profits declining 39.6% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 11.1% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ATHA Price & Volume
Athira Pharma, Inc. (ATHA) stock price & volume — 10-year historical chart
Loading chart...
ATHA Growth Metrics
Athira Pharma, Inc. (ATHA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-8.94%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM2.37%
Return on Capital
10 Years-100.39%
5 Years-93.45%
3 Years-136.22%
Last Year-226.52%
ATHA Peer Comparison
Athira Pharma, Inc. (ATHA) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SAVA | 94.44M | 1.96 | -3.76 | -95.77% | ||||
 ACIU | 302.27M | 2.97 | -3.31 | -86.92% | -19.69% | -101.6% | 0.10 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 AVXL | 309.52M | 3.34 | -6.19 | -31.55% | ||||
 NRXP | 84.43M | 3.05 | -2.28 | -157.28% | ||||
 BIIB | 28.15B | 190.68 | 21.59 | 1.39% | 13.92% | 7.55% | 0.38 | |
 LLY | 932.64B | 987.11 | 43.01 | 44.7% | 34.98% | 101.17% | 1.60 | |
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare ATHA vs Peers
Athira Pharma, Inc. (ATHA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATHA Income Statement
Athira Pharma, Inc. (ATHA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 2M | 479K | 0 | 0 | 0 | 68.09M |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -2M▲ 0% | -479K▲ 76.0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | -68.09M▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | 76.05% | 100% | - | - | - |
| Operating Expenses | 5.01M | 4.7M | 18M | 63.54M | 104.02M | 125.47M | 100.9M | 34.18M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.42M | 1.66M | 6.71M | 21.23M | 32.55M | 33.3M | 26.09M | 16.68M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - |
| Research & Development | 3.59M | 3.79M | 13.29M | 42.79M | 61.46M | 93.79M | 70.68M | 17.5M |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | -754K | -2M | -479K | 10M | -1.63M | 4.13M | 0 |
| Operating Income | -5.01M▲ 0% | -5.45M▼ 8.8% | -20M▼ 266.9% | -64.02M▼ 220.2% | -104.02M▼ 62.5% | -125.47M▼ 20.6% | -100.9M▲ 19.6% | -102.27M▼ 1.4% |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -8.78% | -266.95% | -220.19% | -62.47% | -20.62% | 19.58% | -1.35% |
| EBITDA | 0 | -5.45M | -19.99M | -63.54M | -103.17M | -124.5M | -99.93M | -102.27M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | -267.05% | -217.83% | -62.36% | -20.67% | 19.73% | -2.34% |
| D&A (Non-Cash Add-back) | 5.01M | 2K | 2K | 479K | 845K | 969K | 970K | 0 |
| EBIT | -5.09M | -4.82M | -19.59M | -54.85M | -88.86M | -126.94M | -96.78M | 0 |
| Net Interest Income | 76K | -295K | -243K | 334K | -21.1M | 7.64M | 3.96M | 0 |
| Interest Income | 85K | 51K | 124K | 337K | 3.22M | 7.64M | 3.96M | 0 |
| Interest Expense | 9K | 346K | 367K | 3K | 24.32M | 0 | 0 | 0 |
| Other Income/Expense | -88K | 288K | 40K | 9.17M | 8.38M | 7.79M | 3.96M | -3.34M |
| Pretax Income | -5.1M▲ 0% | -5.16M▼ 1.3% | -19.95M▼ 286.6% | -54.85M▼ 174.9% | -95.64M▼ 74.4% | -117.67M▼ 23.0% | -96.94M▲ 17.6% | -105.61M▼ 8.9% |
| Pretax Margin % | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -5.1M▲ 0% | -5.16M▼ 1.3% | -19.95M▼ 286.6% | -54.85M▼ 174.9% | -95.64M▼ 74.4% | -117.67M▼ 23.0% | -96.94M▲ 17.6% | -105.61M▼ 8.9% |
| Net Margin % | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | -1.26% | -286.65% | -174.88% | -74.36% | -23.04% | 17.62% | -8.94% |
| Net Income (Continuing) | -5.1M | -5.16M | -19.95M | -54.85M | -95.64M | -117.67M | -96.94M | -105.61M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.60▲ 0% | -1.40▲ 12.5% | -6.10▼ 335.7% | -14.90▼ 144.3% | -25.30▼ 69.8% | -30.90▼ 22.1% | -25.20▲ 18.4% | -24.70▲ 2.0% |
| EPS Growth % | - | 12.5% | -335.71% | -144.26% | -69.8% | -22.13% | 18.45% | 1.98% |
| EPS (Basic) | -1.60 | -1.40 | -6.10 | -14.90 | -25.30 | -30.90 | -25.20 | -24.70 |
| Diluted Shares Outstanding | 3.26M | 3.26M | 3.25M | 3.69M | 3.77M | 3.8M | 3.85M | 4.28M |
| Basic Shares Outstanding | 3.26M | 3.26M | 3.25M | 3.69M | 3.77M | 3.8M | 3.85M | 4.28M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
ATHA Balance Sheet
Athira Pharma, Inc. (ATHA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 4.9M | 2.16M | 192.34M | 260.8M | 207.53M | 154.73M | 54.84M | 89.46M |
| Cash & Short-Term Investments | 4.82M | 2.06M | 184.68M | 253.76M | 200.34M | 147.42M | 51.27M | 88.33M |
| Cash Only | 3.32M | 2.06M | 60.63M | 110.54M | 95.97M | 90.58M | 48.44M | 69.28M |
| Short-Term Investments | 1.5M | 0 | 124.06M | 143.22M | 104.38M | 56.84M | 2.84M | 19.05M |
| Accounts Receivable | 6K | 7K | 1.3M | 2.34M | 1.23M | 1.63M | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | -1.23M | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 7.19M | 5.68M | 3.57M | 1.13M |
| Total Non-Current Assets | 36K | 29K | 87.23M | 71.21M | 50.62M | 5.52M | 3.94M | 2.69M |
| Property, Plant & Equipment | 0 | 0 | 3.58M | 5.22M | 5.32M | 4.44M | 3.25M | 2.01M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 36K | 0 | 83.51M | 65.94M | 44.83M | 631K | 631K | 0 |
| Other Non-Current Assets | 0 | 29K | 132K | 56K | 475K | 448K | 55K | 686K |
| Total Assets | 4.93M▲ 0% | 2.19M▼ 55.6% | 279.56M▲ 12671.3% | 332.01M▲ 18.8% | 258.15M▼ 22.2% | 160.25M▼ 37.9% | 58.78M▼ 63.3% | 92.15M▲ 56.8% |
| Asset Turnover | - | - | - | - | - | - | - | - |
| Asset Growth % | - | -55.63% | 12671.27% | 18.76% | -22.24% | -37.93% | -63.32% | 56.78% |
| Total Current Liabilities | 572K | 1.27M | 4.41M | 9.29M | 21.43M | 28.84M | 13.13M | 47.5M |
| Accounts Payable | 121K | 421K | 1.16M | 567K | 2.5M | 129K | 319K | 4.59M |
| Days Payables Outstanding | - | - | 211.34 | 432.06 | - | - | - | 24.59 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 414K | 465K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 230K | 1.62M | 1.91M | 15.19M | 23.8M | 12.4M | 47.04M |
| Current Ratio | 8.56x | 1.70x | 43.66x | 28.07x | 9.68x | 5.37x | 4.18x | 1.88x |
| Quick Ratio | 8.56x | 1.70x | 43.66x | 28.07x | 9.74x | 5.37x | 4.18x | 1.88x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 19.25M | 20.64M | 876K | 1.63M | 1.58M | 1.22M | 803K | 16.86M |
| Long-Term Debt | 722K | 1.55M | 0 | 0 | 0 | 0 | 0 | 338K |
| Capital Lease Obligations | 0 | 0 | 876K | 1.63M | 1.58M | 1.22M | 803K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 18.53M | 19.09M | 0 | 0 | 0 | 0 | 0 | 16.52M |
| Total Liabilities | 19.82M | 21.91M | 5.28M | 10.92M | 23.02M | 30.06M | 13.94M | 64.36M |
| Total Debt | 722K | 1.55M | 1M | 1.92M | 1.91M | 1.58M | 1.22M | 803K |
| Net Debt | -2.6M | -503K | -59.63M | -108.62M | -94.06M | -89M | -47.22M | -68.47M |
| Debt / Equity | - | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.03x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | -565.33x | -13.92x | -53.37x | -18283.33x | -3.65x | - | - | - |
| Total Equity | -14.89M▲ 0% | -19.72M▼ 32.5% | 274.28M▲ 1490.7% | 321.08M▲ 17.1% | 235.14M▼ 26.8% | 130.19M▼ 44.6% | 44.84M▼ 65.6% | 27.79M▼ 38.0% |
| Equity Growth % | - | -32.48% | 1490.67% | 17.06% | -26.77% | -44.63% | -65.56% | -38.03% |
| Book Value per Share | -4.56 | -6.05 | 84.43 | 86.96 | 62.32 | 34.24 | 11.65 | 6.50 |
| Total Shareholders' Equity | -14.89M | -19.72M | 274.28M | 321.08M | 235.14M | 130.19M | 44.84M | 27.79M |
| Common Stock | 3K | 0 | 3K | 4K | 4K | 4K | 4K | 1K |
| Retained Earnings | -15.93M | -21.09M | -41.04M | -95.89M | -191.53M | -309.21M | -406.15M | -511.75M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -17.05M | 0 | 33K | -388K | -1.96M | -349K | 1K | -4K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ATHA Cash Flow Statement
Athira Pharma, Inc. (ATHA) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -4.48M | -3.71M | -24.11M | -43.1M | -72.47M | -100.75M | -97.17M | -45.73M |
| Operating CF Margin % | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | 17.18% | -549.42% | -78.73% | -68.15% | -39.03% | 3.56% | 52.94% |
| Net Income | -5.1M | -5.16M | -19.95M | -54.85M | -95.64M | -117.67M | -96.94M | -105.61M |
| Depreciation & Amortization | 0 | 0 | 251K | 479K | 1.05M | 969K | 455K | 643K |
| Stock-Based Compensation | 196K | 253K | 633K | 4.62M | 0 | 10.62M | 11.05M | 6.1M |
| Deferred Taxes | 0 | 0 | -251K | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 173K | 517K | 1.65M | 648K | 10.18M | -1.2M | 248K | 53.13M |
| Working Capital Changes | 245K | 678K | -6.45M | 6M | 11.94M | 6.53M | -11.98M | 0 |
| Change in Receivables | 0 | 0 | -1.3K | -1.04M | 1.11M | -401K | 1.63M | 0 |
| Change in Inventory | 0 | 0 | 1.3K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 291K | 701K | 2.6M | 5.15M | 2.1M | 7.37M | -5.75M | -21.34M |
| Cash from Investing | 2.01M | 1.51M | -210.07M | -4.08M | 57.66M | 95.09M | 54.83M | -15.89M |
| Capital Expenditures | 0 | 0 | -2.32M | -1.57M | -1.14M | -304K | -33K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 7K | 6K | 36K | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.46M | 946K | 292.75M | 97.09M | 654K | 493K | 194K | 82.46M |
| Debt Issued (Net) | 1.27M | 874K | 1.66M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 100K | 72K | 290.44M | 96.76M | 654K | 493K | 194K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 98K | 0 | 643K | 327K | 0 | 0 | 0 | 82.46M |
| Net Change in Cash | -1.01M▲ 0% | -1.26M▼ 24.6% | 58.57M▲ 4744.6% | 49.91M▼ 14.8% | -14.57M▼ 129.2% | -5.17M▲ 64.5% | -42.15M▼ 715.0% | 20.84M▲ 149.4% |
| Free Cash Flow | -4.48M▲ 0% | -3.71M▲ 17.2% | -26.43M▼ 611.9% | -44.67M▼ 69.0% | -73.61M▼ 64.8% | -101.06M▼ 37.3% | -97.2M▲ 3.8% | -45.73M▲ 53.0% |
| FCF Margin % | - | - | - | - | - | - | - | - |
| FCF Growth % | - | 17.18% | -611.9% | -69% | -64.78% | -37.29% | 3.81% | 52.96% |
| FCF per Share | -1.37 | -1.14 | -8.14 | -12.10 | -19.51 | -26.58 | -25.26 | -10.69 |
| FCF Conversion (FCF/Net Income) | 0.88x | 0.72x | 1.21x | 0.79x | 0.76x | 0.86x | 1.00x | 0.43x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ATHA Key Ratios
Athira Pharma, Inc. (ATHA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -15.68% | -18.43% | -34.39% | -64.42% | -110.77% | -290.81% |
| Return on Invested Capital (ROIC) | - | - | -15.43% | -22.48% | -44.13% | -103.25% | -389.99% | - |
| Debt / Equity | - | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.03x | 0.03x |
| Interest Coverage | -565.33x | -13.92x | -53.37x | -18283.33x | -3.65x | - | - | - |
| FCF Conversion | 0.88x | 0.72x | 1.21x | 0.79x | 0.76x | 0.86x | 1.00x | 0.43x |
ATHA SEC Filings & Documents
Athira Pharma, Inc. (ATHA) SEC filings — annual & quarterly reports (10-K, 10-Q)
ATHA Frequently Asked Questions
Athira Pharma, Inc. (ATHA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Athira Pharma, Inc. (ATHA) grew revenue by 0.0% over the past year. Growth has been modest.
Athira Pharma, Inc. (ATHA) reported a net loss of $105.6M for fiscal year 2025.
Dividend & Returns
Athira Pharma, Inc. (ATHA) has a return on equity (ROE) of -290.8%. Negative ROE indicates the company is unprofitable.
Athira Pharma, Inc. (ATHA) had negative free cash flow of $45.7M in fiscal year 2025, likely due to heavy capital investments.
Explore More ATHA
Athira Pharma, Inc. (ATHA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates